|
Cardiogenesis Enrolls First Two Patients In Its Feasibility Study Of The PHOENIX® Combination Delivery System |
|
Τετάρτη, 13 Οκτώβριος 2010 02:00 |
 |
 |
 |
|
Cardiogenesis Corporation (OTCQB: CGCP), a leading developer of surgical products used in the treatment of diffuse coronary artery disease, reported the enrollment of the first two patients in its PHOENIX Feasibility Study. Dr. Guillermo Reyes at La Princesa Hospital, Madrid, Spain performed the procedures utilizing the company's proprietary PHOENIX System that combines the intramyocardial delivery of stem cells with transmyocardial revascularization (TMR). "Myocardial stimulation via TMR has been proven to reduce angina for the majority of treated patients... (Source: Health News from Medical News Today)
Source: www.medworm.com
|
